NOTICES

• Request for Information on the Development of the FY 2019 Trans-NIH Plan for HIV-Related Research (NOT-OD-17-053)
  Office of AIDS Research

• Notice of Correction for RFA-OD-17-002 "Center for Coordination of Analytics, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54)" (NOT-OD-17-054)
  National Institutes of Health Office of Disease Prevention

• Notice of Correction for RFA-OD-17-006 "Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)" (NOT-OD-17-055)
  National Institutes of Health Office of Disease Prevention

• Guidance for Adjustments to Appointment Records in xTrain to Reflect Stipend Level Increases for Postdoctoral Trainees on Institutional Ruth L. Kirschstein National Research Service Awards (NRSA) (NOT-OD-17-057)
  National Institutes of Health

• Notice of Form Correction for PA-16-286 "Successor-in-Interest (Type 6 Parent)" (NOT-OD-17-058)
  National Institutes of Health

• Notice of Intent to Publish a Funding Opportunity Announcement for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers Research Centers (P50) (NOT-AR-18-006)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Heart, Lung, and Blood Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Neurological Disorders and Stroke

• Notice of Intent to Publish a Funding Opportunity Announcement for Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) (NOT-AR-18-007)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases

• Notice of Informational Webinars for Investigators Applying for NCCIH Clinical Trials (NOT-AT-17-009)
  National Center for Complementary and Integrative Health

• Notice of Change to Key Dates in PAR-16-111 "Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01)" (NOT-CA-17-048)
  National Cancer Institute

• Notice of Pre-application Webinar for PAR-16-131 Emerging Questions in Cancer Systems Biology (U01) (NOT-CA-17-049)
  National Cancer Institute

• Notice of Change in the Expiration Date for PA-14-162 "Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21)" (NOT-DA-17-017)
  National Institute on Drug Abuse

• Notice of Change in the Expiration Date for PA-14-164 "Effects of Cannabis Use and Cannabinoids on the Developing Brain (R03)" (NOT-DA-17-018)
  National Institute on Drug Abuse

• Notice of Change in the Expiration Date for PA-14-163 "Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01)" (NOT-DA-17-019)
  National Institute on Drug Abuse

• Notice of Change in the Expiration Date for PA-14-083 "Neuroimmune Signaling and Function in Substance Use Disorders (R21)" (NOT-DA-17-020)
  National Institute on Drug Abuse

• Notice of Change in the Expiration Date for PA-14-084 "Neuroimmune Signaling and Function in Substance Use Disorders (R01)" (NOT-DA-17-021)
  National Institute on Drug Abuse

• Notice of Change in the Expiration Date for PAR-14-225 Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01) (NOT-DA-17-022)
  National Institute on Drug Abuse, National Center for Complementary and Integrative Health, National Cancer Institute
- Notice of Change in the Expiration Date for PA-15-099 "Reductions in Illicit Drug Use and Functional Outcomes (R21/R33)" (NOT-DA-17-023)
  National Institute on Drug Abuse
- RFP Notice: Pharmacokinetic and Pharmacodynamic Studies for Medications Development (NOT-DA-17-062)
  National Institute on Drug Abuse
- Notice to Extend PAR-15-024 "Food Specific Molecular Profiles and Biomarkers of Food and Nutrient Intake, and Dietary Exposure (R01) (NOT-DK-17-011)
  National Institute of Diabetes and Digestive and Kidney Diseases
- Advancing Conformance with the Voluntary National Retail Food Regulatory Program Standards (VNRFRPS) (U18) (NOT-FD-17-007)
  Food and Drug Administration
- Notice of NICHD's Participation in PAR-17-221 "Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25)"
  (NOT-HD-17-011)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Correction for AHRQ Consumer Assessment of Healthcare Providers and Systems V (U18) FOA (NOT-HS-17-012)
  Agency for Healthcare Research and Quality
- Request for Information (RFI): Input on Opportunities of Engagement of External Stakeholders With the Illuminating the Druggable Genome (IDG) Program (NOT-RM-17-017)
  NIH Roadmap Initiatives
- Change to NIH Method of Payment for Awards to Federal Institutions and Individual Fellowships at Federal Sponsoring Institutions (NOT-OD-17-052)
  National Institutes of Health
- NIAA Policy for Submission of Applications Containing Genome-Wide Association Studies (NOT-AA-17-002)
  National Institute on Alcohol Abuse and Alcoholism
- Notice of Change to the Eligible Activity Codes for PA-17-164 "Aging Biology Research to Address Health Disparities (Admin Supp)"
  (NOT-AG-17-006)
  National Institute on Aging
- Notice of Expiration of PA-16-372 "Small Grants on Primary Immunodeficiency Diseases (R03)"
  (NOT-AI-17-021)
  National Institute of Allergy and Infectious Diseases
- Notice of Expiration of PA-16-373, Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) (NOT-AI-17-022)
  National Institute of Allergy and Infectious Diseases
- Notice of Budget Caps for Applications and Other Submission Requirements in PAR-15-164 "HIV Vaccine Research and Design (HIVRAD) Program (P01)"
  (NOT-AI-17-023)
  National Institute of Allergy and Infectious Diseases
- Notice of Change to PA-17-239 "Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01)"
  (NOT-CA-17-046)
  National Cancer Institute, National Human Genome Research Institute, National Institute of Dental and Craniofacial Research
- Notice of Change to PA-17-243, "Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21)"
  (NOT-CA-17-047)
  National Cancer Institute
- Notice of Change in the Expiration Date for PA-14-038 Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01)
  (NOT-DA-17-014)
  National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism
- Notice of Change in the Expiration Date PA-14-037 "Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03)"
  (NOT-DA-17-015)
  National Institute on Drug Abuse
- Notice of Change in the Expiration Date for PA-14-036 "Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21)"
  (NOT-DA-17-016)
  National Institute on Drug Abuse
REQUEST FOR APPLICATIONS

**TITLE:** Intensive Longitudinal Analysis of Health Behaviors: Leveraging New Technologies to Understand Health Behaviors (U01 & U24)

**SPONSOR:** National Institutes of Health, Office of Behavioral and Social Sciences Research, National Cancer Institute

**Synopsis:** This Funding Opportunity Announcement (FOA) encourages applications to support Research Projects studying factors that influence key health behaviors at the individual level, using intensive longitudinal data collection and analytic methods. The network will also assess how study results can be leveraged to introduce innovations into longstanding behavioral theories to advance the field of theory-driven behavior change interventions.

**Application Receipt Date(s): Multiple dates, see announcement**
**TITLE:** SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44)  
**SPONSOR:** National Cancer Institute  
**Synopsis:** This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and/or in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.  
**Application Receipt Date(s):** July 6, 2017

**TITLE:** Limited Competition: Palliative Care Research Cooperative (PCRC) (U2C)  
**SPONSOR:** National Institute of Nursing Research  
**Application Receipt Date(s):** August 15, 2017

**PROGRAM ANNOUNCEMENTS**

**TITLE:** Academic Research Enhancement Award (Parent R15)  
**SPONSOR:** United States Department of Health and Human Services (HHS) National Institutes of Health (NIH)  
**Synopsis:** The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation’s research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation’s biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students to meritorious research projects, and to strengthen the research environment of the applicant institution.  
**Application Receipt/Submission Date(s):** Multiple dates, see announcement

**TITLE:** NINDS Program Project Grant (P01)  
**SPONSOR:** National Institute of Neurological Disorders and Stroke  
**Application Receipt/Submission Date(s):** Multiple dates, see announcement

**TITLE:** Lasker Clinical Research Scholars Program Si2/R00  
**SPONSOR:** National Institutes of Health, National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research  
**Synopsis:** This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program.  
**Application Receipt/Submission Date(s):** August 25, 2017

**TITLE:** Health Information Technology (IT) to Improve Health Care Quality and Outcomes (R21)  
**SPONSOR:** Agency for Healthcare Research and Quality  
**Application Receipt/Submission Date(s):** Multiple dates, see announcement
• **TITLE:** Implementation and Evaluation of New Health Information Technology (IT) Strategies for Collecting and Using Patient-Reported Outcome (PRO) Measures (U18)  
  *(PA-17-247)*  
  **SPONSOR:** Agency for Healthcare Research and Quality  
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• **TITLE:** Activities to Promote Research Collaborations on Immune-Related Adverse Events (APRC-irAEs) Associated with Cancer Immunotherapy (Admin Supp)  
  *(PA-17-248)*  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** The overarching goal of this Funding Opportunity Announcement (FOA) is to support collaborative pilot projects to generate new ideas and approaches to reduce the incidence and/or severity of auto-inflammatory or autoimmune adverse events in the setting of cancer immunotherapy. In order to facilitate formation of multidisciplinary teams with expertise in mechanisms of cancer immunology/immunotherapy as well as immune tolerance and/or autoimmunity, teams that include (a) a current NCI grantee and a current NIAID grantee, or (b) a current NCI grantee and a current NIAMS grantee, are encouraged to propose collaborative pilot projects that utilize their complementary and synergistic expertise.  
  Application Receipt/Submission Date(s): June 15, 2017

• **TITLE:** Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)  
  *(PAR-17-244)*  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** The overarching goal of this Funding Opportunity Announcement (FOA) is to support collaborative pilot projects to generate new ideas and approaches to reduce the incidence and/or severity of auto-inflammatory or autoimmune adverse events in the setting of cancer immunotherapy. In order to facilitate formation of multidisciplinary teams with expertise in mechanisms of cancer immunology/immunotherapy as well as immune tolerance and/or autoimmunity, teams that include (a) a current NCI grantee and a current NIAID grantee, or (b) a current NCI grantee and a current NIAMS grantee, are encouraged to propose collaborative pilot projects that utilize their complementary and synergistic expertise.  
  Application Receipt/Submission Date(s): Multiple dates, see announcement

**OTHER FUNDING OPPORTUNITIES**  
(Sponsors in bold are NIH Peer Reviewed Organizations)

• **TITLE:** Research Grants  
  [https://www.lungcancerresearchfoundation.org/research/funding-opportunities](https://www.lungcancerresearchfoundation.org/research/funding-opportunities)  
  **SPONSOR:** Lung Cancer Research Foundation (LCRF)

• **TITLE:** Independent Grants for Learning & Change (IGL&C): Request for Proposals - Improving Health Care Capacity in Immuno-Oncology  
  **SPONSOR:** Pfizer, Inc.

• **TITLE:** Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research  
  [http://www.solvingkidscancer.org/researchandgrants/instructions](http://www.solvingkidscancer.org/researchandgrants/instructions)  
  **SPONSOR:** Solving Kids’ Cancer

• **TITLE:** Scholarships  
  **SPONSOR:** Keystone Symposia on Molecular and Cellular Biology